These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Evinacumab for the treatment of homozygous familial hypercholesterolemia. Gao Y; Zhang B; Yang J Expert Rev Clin Pharmacol; 2022 Feb; 15(2):139-145. PubMed ID: 35220876 [TBL] [Abstract][Full Text] [Related]
6. Angiopoietin-like 3 inhibition and the liver: less is more? Oostveen RF; Hovingh GK; Stroes ESG Curr Opin Lipidol; 2023 Dec; 34(6):267-271. PubMed ID: 37820081 [TBL] [Abstract][Full Text] [Related]
7. Will evinacumab become the standard treatment for homozygous familial hypercholesterolemia? Doggrell SA Expert Opin Biol Ther; 2021 Mar; 21(3):299-302. PubMed ID: 33295805 [No Abstract] [Full Text] [Related]
8. Evinacumab: a new option in the treatment of homozygous familial hypercholesterolemia. Pirillo A; Catapano AL Expert Opin Biol Ther; 2022 Jul; 22(7):813-820. PubMed ID: 35698895 [TBL] [Abstract][Full Text] [Related]
14. Evinacumab in Patients with Refractory Hypercholesterolemia. Rosenson RS; Burgess LJ; Ebenbichler CF; Baum SJ; Stroes ESG; Ali S; Khilla N; Hamlin R; Pordy R; Dong Y; Son V; Gaudet D N Engl J Med; 2020 Dec; 383(24):2307-2319. PubMed ID: 33196153 [TBL] [Abstract][Full Text] [Related]
15. A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects. Harada-Shiba M; Ali S; Gipe DA; Gasparino E; Son V; Zhang Y; Pordy R; Catapano AL Atherosclerosis; 2020 Dec; 314():33-40. PubMed ID: 33130482 [TBL] [Abstract][Full Text] [Related]
16. Differential association of plasma angiopoietin-like proteins 3 and 4 with lipid and metabolic traits. Mehta N; Qamar A; Qu L; Qasim AN; Mehta NN; Reilly MP; Rader DJ Arterioscler Thromb Vasc Biol; 2014 May; 34(5):1057-63. PubMed ID: 24626437 [TBL] [Abstract][Full Text] [Related]
17. Angiopoietin-3, a novel member of the angiopoietin family. Nishimura M; Miki T; Yashima R; Yokoi N; Yano H; Sato Y; Seino S FEBS Lett; 1999 Apr; 448(2-3):254-6. PubMed ID: 10218486 [TBL] [Abstract][Full Text] [Related]
18. Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity. Banerjee P; Chan KC; Tarabocchia M; Benito-Vicente A; Alves AC; Uribe KB; Bourbon M; Skiba PJ; Pordy R; Gipe DA; Gaudet D; Martin C Arterioscler Thromb Vasc Biol; 2019 Nov; 39(11):2248-2260. PubMed ID: 31578082 [TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics and exposure-response modeling for evinacumab in homozygous familial hypercholesterolemia. Pu X; Sale M; Yang F; Zhang Y; Davis JD; Al-Huniti N CPT Pharmacometrics Syst Pharmacol; 2021 Nov; 10(11):1412-1421. PubMed ID: 34585515 [TBL] [Abstract][Full Text] [Related]
20. Targeting angiopoietin-like 3 in atherosclerosis: From bench to bedside. Ling P; Zheng X; Luo S; Ge J; Xu S; Weng J Diabetes Obes Metab; 2021 Sep; 23(9):2020-2034. PubMed ID: 34047441 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]